Abstract:During the last years there was a substantial increase in the use of antibodies and related proteins as therapeutics. The emphasis of the pharmaceutical industry is on IgG1, IgG2, and IgG4 antibodies, which are therefore in the focus of this article. In order to ensure appropriate quality control of such biopharmaceuticals, deep understanding of their chemical degradation pathways and the resulting impact on potency, pharmacokinetics, and safety is required. Criticality of modifications may be specific for individual antibodies and has to be assessed for each molecule. However, some modifications of conserved structure elements occur in all or at least most IgGs. In these cases, criticality assessment may be applicable to related molecules or molecule formats. The relatively low dissociation energy of disulfide bonds and the high flexibility of the hinge region frequently lead to modifications and cleavages. Therefore, the hinge region and disulfide bonds require specific consideration during quality assessment of mAbs. In this review, available literature knowledge on underlying chemical reaction pathways of modifications, analytical methods for quantification and criticality are discussed. The hinge region is prone to cleavage and is involved in pathways that lead to thioether bond formation, cysteine racemization, and iso-Asp (Asp, aspartic acid) formation. Disulfide or sulfhydryl groups were found to be prone to reductive cleavage, trisulfide formation, cysteinylation, glutathionylation, disulfide bridging to further light chains, and disulfide scrambling. With regard to potency, disulfide cleavage, hinge cleavage, disulfide bridging to further light chains, and cysteinylation were found to influence antigen binding and fragment crystallizable (Fc) effector functionalities. Renal clearance of small fragments may be faster, whereas clearance of larger fragments appears to depend on their neonatal Fc receptor (FcRn) functionality, which in turn may be impeded by disulfide bond cleavage. Certain modifications such as disulfide induced aggregation and heterodimers from different antibodies are generally regarded critical with respect to safety. However, the detection of some modifications in endogenous antibodies isolated from human blood and the possibility of in vivo repair mechanisms may reduce some safety concerns.

Disulfide Scrambling in IgG2 Monoclonal Antibodies: Insights from Molecular Dynamics Simulations

Disulfide Connectivity of Human Immunoglobulin G2 Structural Isoforms

Interchain Disulfide Bonding in Human IgG2 Antibodies Probed by Site-Directed Mutagenesis

Hinge Disulfides in Human IgG2 CD40 Antibodies Modulate Receptor Signaling by Regulation of Conformation and Flexibility

Human IgG2 Antibodies Display Disulfide-mediated Structural Isoforms

Intrachain disulfide bond in the core hinge region of human IgG4

The inter-heavy chain disulfide bonds of IgG4 are in equilibrium with intra-chain disulfide bonds

Assessment of disulfide and hinge modifications in monoclonal antibodies

Mechanistic insights into inter-chain disulfide bond reduction of IgG1 and IgG4 antibodies

Changes in quaternary structure of IgG upon reduction of the interheavy-chain disulfide bond.

A Simple Analysis of the Second (Extra) Disulfide Bridge of VHHs

Comprehensive elucidation of the structural and functional roles of engineered disulfide bonds in antibody Fc fragment

Engineering an Improved IgG4 Molecule with Reduced Disulfide Bond Heterogeneity and Increased Fab Domain Thermal Stability

One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge.

Contributions of a disulfide bond to the structure, stability, and dimerization of human IgG1 antibody CH3 domain

Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge

Chemical and Structural Analysis of an Antibody Folding Intermediate Trapped During Glycan Biosynthesis

Heterogeneity in Disulfide Bond Reduction in IgG1 Antibodies Is Governed by Solvent Accessibility of the Cysteines

Effects of a reduced disulfide bond on aggregation properties of the human IgG1 CH3 domain

Prevention of Fab-arm exchange and antibody reduction via stabilization of the IgG4 hinge region

Assembly of IgM. Role of disulfide bonding and noncovalent interactions